Loading...
XNAS
HELP
Market cap160mUSD
Jul 09, Last price  
6.63USD
1D
6.42%
1Q
27.01%
IPO
-10.89%
Name

Cybin Inc

Chart & Performance

D1W1MN
XNAS:HELP chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-9.78%
Rev. gr., 5y
%
Revenues
-62m
L
0000864,000000472,270-62,315,175
Net income
-205m
L+81.26%
-127,000-220,806-101,000-1,944,000-32,220,000-71,424,000-40,037,000-78,080,000-113,137,000-205,076,068
CFO
-185m
L+82.30%
2,814-237,026-83,7850-19,027,000-45,207,000-45,207,000-68,908,000-101,300,000-184,669,338

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Cybin Inc. functions as a biopharmaceutical company currently in its clinical development phase, concentrating on the advancement of novel therapeutic agents derived from psychedelic compounds. Its research pipeline includes CYB003, a deuterated psilocybin analog under investigation for major depressive disorder, and CYB004, a deuterated DMT compound being developed to address generalized anxiety disorder.
URL
https://www.cybin.com/
IPO date
Jan 05, 2018
Employees
50
Domiciled in
CA
Incorporated in
CA

Valuation

Title
CAD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑032025‑032024‑032023‑032022‑032021‑032020‑032019‑072018‑072017‑07
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT